2,712 STERIS plc $STE Shares Acquired by Valley National Advisers Inc.

Valley National Advisers Inc. boosted its stake in STERIS plc (NYSE:STE) by 34.0% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 10,691 shares of the medical equipment provider’s stock after purchasing an additional 2,712 shares during the period. Valley National Advisers Inc.’s holdings in STERIS were worth $2,245,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in STE. Signaturefd LLC increased its holdings in shares of STERIS by 31.7% during the third quarter. Signaturefd LLC now owns 1,310 shares of the medical equipment provider’s stock worth $275,000 after buying an additional 315 shares in the last quarter. Citizens Financial Group Inc. RI lifted its stake in shares of STERIS by 35.2% in the 3rd quarter. Citizens Financial Group Inc. RI now owns 1,957 shares of the medical equipment provider’s stock valued at $411,000 after acquiring an additional 510 shares during the last quarter. Taylor Frigon Capital Management LLC lifted its stake in shares of STERIS by 0.9% in the 3rd quarter. Taylor Frigon Capital Management LLC now owns 6,505 shares of the medical equipment provider’s stock valued at $1,366,000 after acquiring an additional 58 shares during the last quarter. Gibbs Wealth Management boosted its holdings in shares of STERIS by 7.0% during the 3rd quarter. Gibbs Wealth Management now owns 2,742 shares of the medical equipment provider’s stock valued at $576,000 after acquiring an additional 179 shares in the last quarter. Finally, Inspire Investing LLC boosted its holdings in shares of STERIS by 8.1% during the 3rd quarter. Inspire Investing LLC now owns 19,098 shares of the medical equipment provider’s stock valued at $4,011,000 after acquiring an additional 1,436 shares in the last quarter. Institutional investors and hedge funds own 94.69% of the company’s stock.

Analysts Set New Price Targets

STE has been the topic of a number of research reports. Piper Sandler restated an “overweight” rating and set a $275.00 price objective (up from $270.00) on shares of STERIS in a research report on Friday, August 7th. Wall Street Zen downgraded STERIS from a “strong-buy” rating to a “buy” rating in a research report on Sunday, October 11th. Weiss Ratings reiterated a “hold (c)” rating on shares of STERIS in a research report on Monday, August 24th. Finally, UBS Group cut their price target on STERIS from $275.00 to $270.00 and set a “buy” rating on the stock in a research note on Friday, August 7th. Three equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat.com, STERIS has an average rating of “Moderate Buy” and an average price target of $271.33.

Insiders Place Their Bets

In other STERIS news, Director Mohsen Sohi sold 4,058 shares of STERIS stock in a transaction that occurred on Wednesday, August 12th. The stock was sold at an average price of $235.78, for a total value of $956,795.24. Following the completion of the sale, the director directly owned 24,305 shares in the company, valued at approximately $5,730,632.90. The trade was a 14.31% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 1.12% of the company’s stock.

STERIS Stock Performance

STE stock opened at $232.27 on Friday. The stock has a 50-day moving average price of $220.09 and a 200-day moving average price of $218.16. STERIS plc has a 1-year low of $195.14 and a 1-year high of $269.44. The company has a current ratio of 1.91, a quick ratio of 1.35 and a debt-to-equity ratio of 0.23. The firm has a market cap of $22.65 billion, a PE ratio of 28.39 and a beta of 0.92.

STERIS (NYSE:STE) last announced its quarterly earnings data on Wednesday, August 5th. The medical equipment provider reported $2.59 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.49 by $0.10. STERIS had a return on equity of 14.34% and a net margin of 13.34%. The company had revenue of $1.49 billion for the quarter, compared to the consensus estimate of $1.49 billion. During the same period in the previous year, the business earned $2.34 EPS. The firm’s revenue was up 7.3% compared to the same quarter last year. STERIS has set its FY 2027 guidance at 11.000-11.300 EPS. As a group, equities research analysts expect that STERIS plc will post 11.12 earnings per share for the current year.

STERIS Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, September 25th. Shareholders of record on Friday, September 4th were issued a $0.69 dividend. The ex-dividend date was Friday, September 4th. This is an increase from STERIS’s previous quarterly dividend of $0.63. This represents a $2.76 dividend on an annualized basis and a yield of 1.2%. STERIS’s dividend payout ratio is presently 33.74%.

STERIS Company Profile

STERIS plc (NYSE: STE) provides products and services designed to support infection prevention, procedural care and the safe manufacture of healthcare and life sciences products. Its offerings include surgical equipment and operating-room solutions, sterilization and decontamination systems, endoscopy products, cleaning and disinfection technologies, and related consumable products.

The company also provides outsourced sterilization and laboratory services through its Applied Sterilization Technologies business.